European Bionetwork Summit

As many products come off patent, this is causing ‘game-changing' falls in revenues.
Consequently, industry is grappling with questions pertaining to the most effective strategies for developing meaningful new drugs and how it should collectively fund and reward their discovery and development activities.

Gone are the days that pharma companies can 'go it alone'.
As a result, companies in the life sciences sector must think creatively in order to gain maximum potential and benefits from their partnering and collaboration strategies and models.